de Figueiredo Peloso Eduardo, Merli Rafaella Junqueira, Espuri Patrícia Ferreira, Nunes Juliana Barbosa, Colombo Fábio Antônio, Sierra Elkin José Torres, de Paulo Daniela Carvalho, Dos Santos Marcelo Henrique, Carvalho Diogo Teixeira, Marques Marcos José
Department of Biochemistry, Institute of Biomedical Sciences, Universidade Federal de Alfenas, 700 Gabriel Monteiro da Silva St, Alfenas, MG, CEP 37130-001, Brazil.
Laboratory of Parasitology, Department of Pathology and Parasitology, Institute of Biomedical Sciences, Universidade Federal de Alfenas, 700 Gabriel Monteiro da Silva St, Alfenas, MG, CEP 37130-001, Brazil.
Mol Biol Rep. 2020 Nov;47(11):8465-8474. doi: 10.1007/s11033-020-05887-5. Epub 2020 Oct 6.
Changes in host immunity and parasite resistance to drugs are among the factors that contribute to decreased efficacy of antiparasitic drugs such as the antimonial compounds pentamidine, amphotericin (AMP B) and miltefosine. Bioactive natural products could be alternatives for the development of new drugs to treat neglected human diseases such as leishmaniasis. Natural coumarins and synthetic analogues have shown leishmanicidal activity, mainly in vitro. This study investigated the in vitro and in vivo leishmanicidal activity of synthetic coumarin compounds (C1-C5) in parasites Leishmania (L.) amazonensis and L. (L.) infantum chagasi. The cytotoxicity of these compounds in mammalian cells and their influence on production of reactive oxygen species was also investigated. In vitro assays showed that 8-methoxy-3-(4-nitrobenzoyl)-6-propyl-2H-chromen-2-one (C4) was as active as AMP B mainly in the amastigote form (p < 0.05); C4 presented a selectivity index (65.43) four times higher than C2 (15.4) in L. amazonensis and six times higher (33.94) than C1 (5.46) in L. infantum chagasi. Additionally, coumarin C4 reduced the HO concentration 32.5% more than the control group in L. amazonensis promastigotes during the lag phase of proliferation. No interference of C4 was observed on the mitochondrial membrane potential of the parasites. In vivo, coumarin C4 in corn oil (oral route) led to a reduction in the number of amastigotes from L. infantum chagasi to 1.31 × 10 and 4.09 × 10 in the spleen and liver, respectively (p < 0.05). Thus, C4 represents a candidate for further studies aiming at new treatments of leishmaniasis.
宿主免疫力的变化以及寄生虫对药物的抗性是导致抗寄生虫药物(如锑化合物喷他脒、两性霉素B和米替福新)疗效降低的因素。生物活性天然产物可能是开发治疗利什曼病等被忽视的人类疾病新药的替代选择。天然香豆素及其合成类似物已显示出杀利什曼原虫活性,主要是在体外。本研究调查了合成香豆素化合物(C1 - C5)对亚马逊利什曼原虫和婴儿利什曼原虫恰加斯亚种的体外和体内杀利什曼原虫活性。还研究了这些化合物对哺乳动物细胞的细胞毒性及其对活性氧产生的影响。体外试验表明,8 - 甲氧基 - 3 -(4 - 硝基苯甲酰基)- 6 - 丙基 - 2H - 色烯 - 2 - 酮(C4)主要在无鞭毛体形式下与两性霉素B活性相当(p < 0.05);在亚马逊利什曼原虫中,C4的选择性指数(65.43)比C2(15.4)高四倍,在婴儿利什曼原虫恰加斯亚种中比C1(5.46)高六倍(33.94)。此外,在亚马逊利什曼原虫前鞭毛体增殖的延迟期,香豆素C4使HO浓度比对照组降低了32.5%。未观察到C4对寄生虫线粒体膜电位的干扰。在体内,玉米油中的香豆素C4(口服途径)使婴儿利什曼原虫恰加斯亚种在脾脏和肝脏中的无鞭毛体数量分别减少至1.31×10和4.09×10(p < 0.05)。因此,C4是针对利什曼病新治疗方法进一步研究的候选药物。
Exp Parasitol. 2019-6
Exp Parasitol. 2019-4
Basic Clin Pharmacol Toxicol. 2018-4-6
PLoS Negl Trop Dis. 2017-7-13
F1000Res. 2017-5-26
PLoS One. 2016-10-21
J Am Acad Dermatol. 2015-12